Breast Cancer clinical trials
Showing 1,001–1,050 of 1,067 active trials. Describe your situation to see which ones you may be eligible for.
- A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
- Clinical Trial to Treat Stage IV Cancer Patients
- Social Needs App for Oncology Patients Phase II
- Quest to Analyze One Thousand Humans Meditating
- Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors
- Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
- Focused Ultrasound and Gemcitabine in Breast Cancer
- Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
- Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
- A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
- Outcomes and Cosmesis With Whole Breast Irradiation and Boost
- Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
- PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
- Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
- Preoperative Irradiation for Stage I Breast Cancer
- A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
- Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
- A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
- A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
- Study of INCB123667 in Subjects With Advanced Solid Tumors
- FaCT Trial (Facilitated Cascade Testing Trial)
- Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women
- Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
- Together After Cancer
- SHAPE Neoadjuvant Chemotherapy Response
- Prospective Case Collection Study for New Mammography Technologies
- RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
- An Ophthalmic Safety Study in Patients With Breast Cancer
- Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients
- Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes
- Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.